Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-05-26 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-05-26 English
Third Quarter Financial Results on Form 6-K 102 pages 751.4KB
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the U.S. SEC by Mesoblast Limited, a foreign private issuer. It covers the three and nine months ended March 31, 2023, and includes unaudited financial statements, management's discussion and analysis, risk factors, and signatures. Form 6-K is a report used by foreign private issuers to provide interim financial information and other material information to the SEC. The presence of unaudited financial statements and management discussion indicates this is an interim or quarterly report rather than a full annual report or other filing. The document is substantive and contains actual financial data and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2023-05-25 English
Third Quarter Results Presentation 34 pages 2.1MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation of operational highlights and financial results for the quarter ended March 31, 2023, including financial data such as revenue, cash burn, capital, and P&L figures. It also contains clinical pipeline updates, regulatory filing status (e.g., BLA accepted for review with PDUFA goal date), and forward-looking statements. The presence of comprehensive financial data and analysis for a specific quarter, along with detailed business and clinical updates, indicates this is a quarterly financial report rather than a brief earnings release or an announcement. The document is about 15,000 characters long, which supports it being a full report rather than a short announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-05-25 English
MSB Reports Q3 Financial Results and Operational Highlights 8 pages 583.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'MESOBLAST REPORTS OPERATIONAL AND FINANCIAL HIGHLIGHTS FOR QUARTER ENDED MARCH 31, 2023' and contains detailed operational and financial results for the quarter ended March 31, 2023. It includes financial highlights such as cash on hand, revenue, net cash usage, expenses, and loss after tax, as well as operational updates and milestones. The document also announces a conference call webcast for discussing these results. The length is substantial (15,000 characters), and it contains substantive financial data and analysis for a quarterly period, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-05-25 English
Regulatory Filings 2023
Regulatory Filings
2023-05-24 English
Regulatory Filings 2023
Regulatory Filings
2023-05-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.